ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company, has announced its participation in three upcoming investor conferences in September 2024:
- 2024 Wells Fargo Healthcare Conference on September 5 at 8:00 a.m. ET
- Baird 2024 Global Healthcare Conference on September 10 at 10:50 a.m. ET (for conference attendees only)
- 2024 Cantor Global Healthcare Conference on September 19 at 8:35 a.m. ET
The company will participate in fireside chats at each event. Live webcasts for the Wells Fargo and Cantor conferences will be available on ORIC's website, with replays accessible for 90 days after the events. This engagement demonstrates ORIC's commitment to investor relations and showcasing its progress in developing treatments for therapeutic resistance in oncology.
ORIC Pharmaceuticals (Nasdaq: ORIC), un'azienda oncologica in fase clinica, ha annunciato la sua partecipazione a tre conferenze per investitori in programma a settembre 2024:
- 2024 Wells Fargo Healthcare Conference il 5 settembre alle 8:00 ET
- Baird 2024 Global Healthcare Conference il 10 settembre alle 10:50 ET (solo per i partecipanti alla conferenza)
- 2024 Cantor Global Healthcare Conference il 19 settembre alle 8:35 ET
L'azienda parteciperà a discussioni informali in ciascun evento. Le trasmissioni in diretta delle conferenze Wells Fargo e Cantor saranno disponibili sul sito web di ORIC, con riproduzioni accessibili per 90 giorni dopo gli eventi. Questo coinvolgimento dimostra l'impegno di ORIC nelle relazioni con gli investitori e la messa in mostra dei suoi progressi nello sviluppo di trattamenti per la resistenza terapeutica in oncologia.
ORIC Pharmaceuticals (Nasdaq: ORIC), una empresa oncológica en etapa clínica, ha anunciado su participación en tres conferencias de inversores que se llevarán a cabo en septiembre de 2024:
- 2024 Wells Fargo Healthcare Conference el 5 de septiembre a las 8:00 a.m. ET
- Baird 2024 Global Healthcare Conference el 10 de septiembre a las 10:50 a.m. ET (solo para asistentes a la conferencia)
- 2024 Cantor Global Healthcare Conference el 19 de septiembre a las 8:35 a.m. ET
La empresa participará en charlas informales en cada evento. Las transmisiones en vivo de las conferencias Wells Fargo y Cantor estarán disponibles en el sitio web de ORIC, con repeticiones accesibles durante 90 días después de los eventos. Este compromiso demuestra la dedicación de ORIC a las relaciones con los inversores y a mostrar su progreso en el desarrollo de tratamientos para la resistencia terapéutica en oncología.
ORIC Pharmaceuticals (Nasdaq: ORIC), 임상 단계의 항암제 회사가 2024년 9월에 개최되는 세 가지 투자자 회의에 참여한다고 발표했습니다:
- 2024 웰스파고 헬스케어 컨퍼런스, 9월 5일 오전 8:00 ET
- 베어드 2024 글로벌 헬스케어 컨퍼런스, 9월 10일 오전 10:50 ET (참가자만 해당)
- 2024 칸토르 글로벌 헬스케어 컨퍼런스, 9월 19일 오전 8:35 ET
회사는 각 행사에서 비공식 토론에 참여합니다. 웰스파고와 칸토르 컨퍼런스의 생중계는 ORIC의 웹사이트에서 제공되며, 이벤트 후 90일 동안 재방송이 가능합니다. 이번 참여는 투자자 관계와 항암제에서 치료 저항성 개발에 대한 ORIC의 진전을 보여주려는 의지를 나타냅니다.
ORIC Pharmaceuticals (Nasdaq: ORIC), une entreprise d'oncologie en phase clinique, a annoncé sa participation à trois conférences pour investisseurs à venir en septembre 2024 :
- Conférence de santé Wells Fargo 2024 le 5 septembre à 8h00 ET
- Conférence de santé mondiale Baird 2024 le 10 septembre à 10h50 ET (réservé aux participants de la conférence)
- Conférence de santé mondiale Cantor 2024 le 19 septembre à 8h35 ET
L'entreprise participera à des discussions informelles lors de chaque événement. Les diffusions en direct des conférences Wells Fargo et Cantor seront disponibles sur le site internet d'ORIC, avec des rediffusions accessibles pendant 90 jours après les événements. Cette participation démontre l'engagement d'ORIC envers les relations avec les investisseurs et la présentation de ses progrès dans le développement de traitements pour la résistance thérapeutique en oncologie.
ORIC Pharmaceuticals (Nasdaq: ORIC), ein Unternehmen in der klinischen Phase der Onkologie, hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen im September 2024 angekündigt:
- Wells Fargo Healthcare Conference 2024 am 5. September um 8:00 Uhr ET
- Baird 2024 Global Healthcare Conference am 10. September um 10:50 Uhr ET (nur für Kongressteilnehmer)
- 2024 Cantor Global Healthcare Conference am 19. September um 8:35 Uhr ET
Das Unternehmen wird an informellen Gesprächen bei jeder Veranstaltung teilnehmen. Die Live-Übertragungen der Wells Fargo- und Cantor-Konferenzen werden auf der Website von ORIC verfügbar sein, und Wiederholungen sind 90 Tage nach den Veranstaltungen zugänglich. Dieses Engagement zeigt ORICs Commitment zu den Beziehungen zu Investoren und die Präsentation seiner Fortschritte bei der Entwicklung von Therapien gegen therapeutische Resistenzen in der Onkologie.
- None.
- None.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in September:
- 2024 Wells Fargo Healthcare Conference – Participating in a fireside chat on Thursday, September 5, 2024, at 8:00 a.m. ET
- Baird 2024 Global Healthcare Conference (Available to conference attendees only) – Participating in a fireside chat on Tuesday, September 10, 2024, at 10:50 a.m. ET.
- 2024 Cantor Global Healthcare Conference – Participating in a fireside chat on Thursday, September 19, 2024, at 8:35 a.m. ET
Live webcasts of the Wells Fargo and Cantor discussions will be available through the investor section of the company’s website at www.oricpharma.com. Replays of the webcasts will be available for 90 days following the events.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma. Beyond these three product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
FAQ
What investor conferences will ORIC Pharmaceuticals participate in during September 2024?
Will ORIC Pharmaceuticals' conference presentations be available for public viewing?
What is the focus of ORIC Pharmaceuticals' research and development?
When is ORIC Pharmaceuticals scheduled to present at the 2024 Wells Fargo Healthcare Conference?
